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Abstract 
A 75-year old man was detected with a pedic-
ulate tumor in the upper esophagus. A biopsy
determined that it was an adenocarcinoma. A
subtotal  esophagectomy  with  dissection  of
three-fields of lymph nodes was selected. The
pathological  study  revealed  it  to  be  an
esophageal  adenocarcinoma  arising  from
ectopic gastric mucosa of the fundus of the
stomach.  His  post-operative  course  was
uneventful and without sign of recurrence for
3.5 years.
Introduction
Esophageal  adenocarcinomas  arising  from
ectopic  gastric  mucosa  (EAEGM)  have  been
reported in only 26 cases worldwide, therefore
therapy for this condition is still inconsistent.
The available therapeutic strategies for surgi-
cal treatment, chemotherapy and/or radiation
will  be  discussed  from  experience  with  the
present case, and in reference to past reported
cases. This is the first report to discuss the
clinical features and treatment for EAEGM.
Case Report
A  75-year  old  man  underwent  a  medical
examination without any complications. Since
an upper gastrointestinal X-ray showed a sim-
ple shaped tumor, 20 mm in size (Figure 1a),
detailed studies were selected. On laboratory
blood  examination,  no  abnormal  data  were
found  except  for  slight  anemia  and  a  high
value of squamous cell carcinoma-related anti-
gen, 1.3 ng/mL (normal range; <1.5 ng/mL). An
upper  gastrointestinal  endoscopy  detected  a
pediculate  tumor,  25  mm  in  size,  with  easy
bleeding  in  the  upper  thoracic  esophagus
(invasive  level;  muscularis  propria)  (cT2)
(Figure 1b), and pathological findings from a
biopsied specimen revealed a moderately dif-
ferentiated  tubular  adenocarcinoma.  With
chest  and  abdominal  computed  tomography
(CT), a primary pediculate tumor, 30¥20 mm
in size, with regional lymphnode swelling (N1)
was  noted  without  any  metastasis  or  direct
invasion to other organs (M0). According to
the  UICC  6th  edition  staging  system,  the
tumor  was  indicated  as  cStage  IIB,  and  a
subtotal  esophagectomy  with  lymph-node
clearing  was  performed  in  April,  2006.  On
removal, a type I tumor, 35¥22 mm in size, was
observed on the esophagus, and it stained neg-
ative with lugol solution (Figure 2). In addi-
tion, the esophageal mucosa surrounding the
tumor was also negative for lugol solution, sug-
gesting that the tumor arose from the ectopic
mucosa. The pathological study demonstrated
the presence of a tubular papillary and solid
type EAEGM (pStage: I, invasion level: mucosa,
lymphatic duct invasion: not detected, vessel
invasion: not detected) (Figure 3), and lymph
node metastasis was not noted. The patient is
currently in good health without any problems.
Discussion
Primary esophageal adenocarcinomas that
match the following diagnostic criteria repre-
sent 0.76% of all the cases of carcinoma of the
esophagus or cardia; i) a tumor localized in
the esophagus from the cricoid cartilage to the
cardiac orifice; ii) a tumor arising from the
esophageal glands; iii) a tumor that has tis-
sues  of  the  glands,  and  where  there  are
lesions of the carcinoma discharging mucus
on the inside of the tumor; iv) existence of
normal squamous epithelium in the anal side
of the tumor, or a tumor that exists in an area
apart from the cardiac orifice; v) no primary
cancerous  lesions  in  the  other  organs.
1,2
Because  the  incidence  of  ectopic  gastric
mucosa  has  been  detected  in  only  4.0%  of
males and 2.9% of females,
3 carcinogenesis at
Figure 1. Upper gastrointestinal X-ray
and  endoscopic  examination.  Barium
esophagogram  (a)  (arrow)  and  upper
gastrointestinal endoscopy (b) showed a
pediculate tumor, 20 mm in size, which
was  detected  in  the  upper  thoracic
esophagus. 
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reported worldwide as shown in Table 1.
4-25 The
age of these patients ranged from 37 to 85
years, and the tumor size was between 1.9 and
7.0 cm (mean; 3.9 cm). The nature of invasion
into surrounding tissues was found to be to
the  submucosal  level  in  9  cases,  muscular
invasion in 4 cases and advanced invasion in
9 cases, with 3 cases unknown. If the degree
of  layer  invasion  and  tumor  size  are  com-
pared, the average tumor size was 3.4 cm in
submucosal  invasion,  4.3  cm  in  advanced
invasion  and  4.5  cm  in  muscular  invasion,
suggesting  that  the  tumor  size  (width  of
growth) might be associated with the degree
of  layer  invasion  (invasive  level  of  tumor).
However, the prognosis was not exactly indi-
cated by tumor size, because in patients with
big tumors, such as 5 cm or 6.5 cm, there may
be no signs of recurrence, whereas tumors as
small as 2 or 3 cm could lead to recurrence.
Focusing on the nature of the layer invasion to
estimate the most favorable therapeutic strat-
egy in submucosal invasion cases, esophagec-
tomy  was  an  appropriate  radical  treatment,
but not partial resection, because local resec-
tion alone was found to lead to local recur-
rence. In muscular invasion cases, one of 2
cases  of  esophagectomy  without  additional
therapy led to recurrence, and a case treated
with radiotherapy (RT) and chemoradiothera-
py (CRT) showed a relatively good prognosis.
In advanced cases, with the exception of one
unknown  case  without  detailed  data,
esophagectomy without additional therapy led
to a poor prognosis for 3 cases in 4, and one
Table 1. Twenty-six cases of esophageal adenocarcinoma arising from the ectopic gastric mucosa.
Author and year Age/sex Size(cm) Histological type Depth of invasion  Treatment Prognosis
1. Carrie (1950)
6 64M 3 Adenoca. Muscularis propria Partial esophagectomy Alive (over one year; 
unknown in detail)
2. Davis (1969)
6) 68M 1.8x7 Mucinous adenoca. Submucosa RT+esophagectomy Alive (7 months; 
unknown in detail)
3. Sakamoto (1970)
7 64M 2.5x1.7 Papillary adenoca. Muscularis propria RT+esophagectomy Dead (37 months; cervical 
and inguinal skin meta)
4. Clemente (1974)
8 53M 2.5x2x2 Intestinal type. Adventitia Laryngectomy +  Cervical recurrence
esophagectomy
5. Danoff (1978)
4 43M 6 Poorly diff adenoca. Adventitia RT Dead (2 months)
6. Kamiya (1983)
9 58M 5x3 Moderately diff adenoca. Adventitia Pharyngolaryngectomy+ Dead (7 months; pneumonia)
esophagectomy
7. Schmidt 1 (1985)
10 37M Not  Adenoca. Adventitia Esophagectomy Alive (4 months;
mentioned unknown in detail)
8. Schmidt 2 (1985)
10 54M 3 Adenoca. Submucosa Partial esophagectomy Dead (12 months; local 
recurrence)
9. Endo (1986)
11 73M Not  Adenosquamous ca. Unknown Not resected Dead (12 months)
mentioned
10. Christensen 1 (1987)
12 52M 6x5.5x2 Poorly diff adenoca. Muscularis propria Esophagectomy Dead suspected 
(Abdominal meta)
11. Christensen 2 (1987)
12 50M 4x3.5x1.5 Moderately diff adenoca. Adventitia Esophagogastrectomy Not mentioned
12. Ishii (1991) (13) 66M 5x4.5x3 Well diff adenoca. Submucosa Esophagectomy No rec (20 months)
13. Kubota (1993)
14 58M Not  Papillary adenoca. Adventitia CRT only Dead 
mentioned (12 months; lung meta)
14. Takagi Y (1994)
15 85M 6.8x3 Moderately diff adenoca. Adventitia Transhiatal  Not mentioned
esophagectomy 
15. Takagi A (1995)
16 70M 1.9x1.6 Well diff adenoca. Submucosa Esophagectomy Not mentioned
16. Sperling (1995)
17 79M 2 Poorly diff adenoca. unknown RT Not mentioned
17. Kammori (1996)
18 74F 2x1.5x0.7 Well diff adenoca. Submucosa Mucosal resection No rec. (unknown in 
detail)
18. Pai (1997)
19 60M 3.5x6.5 Moderately diff adenoca. Muscularis propria Esophagectomy+CRT Alive (30 months; 
unknown in detail)
19. Berkelhammer (1997)
20 71M Not  Moderately diff adenoca Submucosa Esophagectomy No rec. (2 years)
mentioned
20. Yamamoto (1997)
21 90F Not  Adenoca. unknown Transhiatal  Not mentioned
esophagectomy 
21. Lauwers (1998)
22 57M 2x4 Moderately diff adenoca. Adventitia Esophagectomy+RT Alive (8 months; unknown 
in detail)
22. Noguchi (2001)
23 73M 2.5x2 Well diff adenoca. Submucosa Esophagectomy No rec (5 years)
23. Kagawa (2001)
24 51M 2x2 Moderately diff adenoca. Adventitia Esophagectomy Dead (11 months; 
lung meta) 
24. Abe (2004)
25 50M 2.5x1.5 Well diff adenoca. Submucosa Esophagectomy No rec (unknown in detail)
25. Alrawi (2004)
5 60M 3.2x3 Moderately diff adenoca. Submucosa Partial esophagectomy No rec (6 years)
+CRT
26. Our case (2006) 75M 3.5x2.2 Adenoca. Mucosa Esophagectomy No rec (42 months)
Adenoca, adenocarcinoma; rec, recurrence; meta, metastasis.
Case Report
[Rare Tumors 2010; 2:e5] [page 13]case  remains  alive  but  is  still  under  short-
term observation. In contrast, one esophagec-
tomy case combined with RT showed a good
outcome.  In  addition,  esophagectomy  com-
bined with radiation or chemo-radiation ther-
apy might result in a favorable outcome, sug-
gesting that additional treatment beyond the
initial  operation  is  critical.  In  the  present
case, since there was no tumor invasion into
the muscular layer, no adjuvant treatment was
required and no signs of recurrence have been
observed. 
The  rate  of  lymph  node  metastases  was
found to be relatively high in the esophagus,
with around 30% of cases showing submucos-
al invasion, compared to 19% in the stomach.
26
Additionally,  distant  metastasis  has  been
noted frequently due to the anatomical char-
acteristic  of  the  esophagus  developing  a
strong  lymphatic  network,
27 indicating  the
importance of aggressive lymph node resec-
tion. In fact, complete surgical resection rep-
resents a first-line treatment for esophageal
adenocarcinomas,  such  as  Barrett’s
esophageal adenocarcinoma.
28 In addition, in
East  Asia,  the  combined  drug  TS-1
(tegafur/gimeracil/oteracil  potassium),  an
oral  5-FU  drug,  is  widely  accepted  as  a
chemotherapeutic  agent  due  to  its  high
response rate; 47% in single use and over 70%
when  used  in  combination  with  other
chemotherapeutic  agents.
29,30 In  contrast,
because TS-1 is not commonly used in North
America and Europe, a combination chemo-
therapy  based  on  infused  5-FU  is  widely
selected as a standard; infused 5-FU and cis-
platin or the addition of a third drug (anthra-
cyclines; epirubicin).
31,32The response rate has
been  reported  as  49-56%  against  locally
advanced gastric cancer.
33,34 In conclusion, rad-
ical  surgical  treatment  with  adjuvant
chemotherapy  should  be  considered  for
advanced EAEGM.
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